Hartman ML, Sanyal AJ, Loomba R et al (2020) Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes
Whey protein was studied in a group of obese women pursuing weight loss
The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms
These effects are seen even outside of diabetes control.[ref] Decreased colon cancer mortality: A 5-year mortality study in colon cancer patients showed that GLP-1 RA use decreased mortality risk by 60% in obese patients.[ref] Decreased risk of substance abuse: A large 2026 study using data from the VA showed that GLP-1 RA drugs reduce the risk of developing a substance addiction (drugs, alcohol)
Notably, in high-quality large RCTs, tirzepatide demonstrated greater effectiveness than GLP-1R mono agonists in reducing serum glucose, fat mass, and body weight
Liraglutide Mends Cognitive Impairment by Averting Notch Signaling Pathway Overexpression in a Rat Model of Polycystic Ovary Syndrome
